Related Experiment Videos
Cardiac allograft vasculopathy: current concepts, recent developments, and future directions
J D Hosenpud1, G D Shipley, C R Wagner
1Immunobiology Research Laboratory, Oregon Health Sciences University, Portland 97201.
Insights
Late deaths after heart transplantation remain high due to cardiac allograft vasculopathy, an accelerated coronary artery disease. Understanding its immunologic mechanisms is crucial for developing new treatments beyond repeat transplantation.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Heart transplantation survival has improved, with 1-year mortality below 15%.
- Late mortality remains a significant challenge, largely due to cardiac allograft vasculopathy (CAV).
- CAV is an accelerated form of coronary artery disease unique to transplant recipients.
Purpose of the Study:
- To review the clinical aspects of cardiac allograft vasculopathy.
- To discuss recent experimental findings on CAV mechanisms.
- To explore future research directions for managing CAV.
Main Methods:
- Literature review of clinical outcomes in heart transplantation.
- Analysis of experimental studies investigating CAV pathogenesis.
- Synthesis of current and proposed therapeutic strategies for CAV.
Main Results:
- While early survival post-heart transplant is good, late death is primarily caused by CAV.
- The immunologic basis of CAV is suspected but not definitively confirmed.
- Current treatment options for CAV are limited, with re-transplantation being the only recourse.
Conclusions:
- Cardiac allograft vasculopathy is the main barrier to improving long-term survival after heart transplantation.
- Further research into the immunologic mechanisms of CAV is essential.
- Novel therapeutic approaches are needed to address this accelerated form of coronary artery disease.
Abstract:
Survival after heart transplantation has improved steadily over the past decade, with 1-year mortality rates now less than 15% in most centers. Despite a substantial improvement in early survival, late death has not been significantly impacted. The major cause of late death is due to cardiac allograft vasculopathy, an accelerated form of coronary artery disease. The mechanisms responsible for cardiac allograft vasculopathy are thought to be immunologic; however direct confirmation of this is lacking. Because cardiac allograft vasculopathy is not amenable to traditional therapies for coronary atherosclerosis, to date the only treatment is repeat transplantation. This paper reviews the clinical aspects of cardiac allograft vasculopathy, the recent experimental work, and potential future directions for study.